MedTrace Logo

A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT02774278 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 264

Last updated 2016-08-08

Study results available
· View outcomes & findings →

Summary

This study will assess potentially predictive markers of efficacy in participants with NSCLC receiving oral erlotinib (Tarceva) therapy. The anticipated time on study treatment is until disease progression, unacceptable toxicity or death.

Conditions

  • Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG

Erlotinib

Erlotinib will be administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • Belgium
  • Bulgaria
  • Estonia
  • France
  • Germany
  • Hong Kong
  • Ireland
  • Italy
  • Poland
  • Russia
  • Singapore
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02774278 on ClinicalTrials.gov